Stock listing

NASDAQ:EDIT Editas Medicine, Inc. Stock

Home listing (NASDAQ) of Editas Medicine, Inc.

Follow Editas Medicine, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:EDIT

$1.64 USD -0.13 (-7.3%)

Close on Nov 20, 2026

Past year -33.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.63 – $1.78 USDNov 20, 2026
Volume
2.68M sharesNov 20, 2026
Market cap
$253.1M USDAt the close on Nov 20, 2026 · price × 154.3M shares outstanding
52-week range
$1.63 – $3.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.14M USDMedian day 2.27M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Editas Medicine, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:EDIT · Home$1.64 USD-0.13 (-7.3%)2,679,287$1.69$1.78$1.63$1.77Close on Nov 20, 2026
LSE:0IFK$1.678 USD-0.102 (-5.7%)11,320$1.81$1.81$1.66$1.78Close on Nov 20, 2026
Frankfurt:8EM€1.545 EUR-0.145 (-8.6%)—€1.545€1.545€1.545€1.69Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EDIT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.64-0.13-7.3%$1.69$1.78$1.632,679,287
$1.77-0.055-3.0%$1.86$1.945$1.761,989,397
$1.825-0.045-2.4%$1.90$1.937$1.822,022,580
$1.87-0.30-13.8%$2.10$2.12$1.862,105,770
$2.17+0.03+1.4%$2.14$2.21$2.012,785,410
$2.14-0.24-10.1%$2.32$2.32$2.123,881,551
$2.38-0.125-5.0%$2.51$2.52$2.361,968,902
$2.505-0.245-8.9%$2.70$2.75$2.481,589,910
$2.75+0.18+7.0%$2.63$3.005$2.5113,719,634
$2.57+0.02+0.8%$2.55$2.63$2.4751,715,866
$2.55-0.17-6.3%$2.68$2.68$2.412,096,971
$2.72+0.12+4.6%$2.70$2.79$2.612,368,229
$2.60+0.03+1.2%$2.61$2.71$2.571,755,820
$2.57-0.10-3.7%$2.71$2.778$2.551,236,276
$2.67-0.26-8.9%$2.89$2.92$2.602,908,802
$2.93-0.02-0.7%$2.945$2.98$2.863,224,947
$2.95+0.35+13.5%$2.59$2.96$2.544,407,190
$2.60+0.20+8.3%$2.41$2.61$2.3713,078,317
$2.400.000.0%$2.39$2.445$2.361,350,754
$2.40-0.09-3.6%$2.44$2.45$2.301,313,712
$2.49-0.02-0.8%$2.47$2.58$2.451,066,486
$2.51-0.07-2.7%$2.59$2.60$2.501,139,426
$2.58+0.16+6.6%$2.40$2.665$2.352,266,488
$2.42+0.07+3.0%$2.38$2.43$2.272,010,947
$2.35-0.09-3.7%$2.44$2.47$2.331,551,300
$2.44+0.17+7.5%$2.26$2.465$2.251,858,600
$2.27-0.175-7.2%$2.44$2.475$2.2452,827,200
$2.445-0.305-11.1%$2.73$2.73$2.442,449,700
$2.75-0.15-5.2%$2.90$2.91$2.731,296,400
$2.90+0.06+2.1%$2.85$2.97$2.713,087,100
$2.84+0.09+3.3%$2.79$2.945$2.696,067,000
$2.75+0.02+0.7%$2.71$2.845$2.6592,264,700
$2.73-0.06-2.2%$2.85$2.895$2.7152,967,500
$2.79+0.17+6.5%$2.62$2.81$2.5553,012,000
$2.62+0.10+4.0%$2.57$2.63$2.512,162,800
$2.52-0.05-1.9%$2.61$2.62$2.521,544,200
$2.57-0.02-0.8%$2.61$2.72$2.551,624,500
$2.59+0.08+3.2%$2.54$2.62$2.511,568,500
$2.51-0.07-2.7%$2.55$2.55$2.422,203,200
$2.58-0.17-6.2%$2.76$2.78$2.573,117,600
$2.75+0.06+2.2%$2.66$2.76$2.5452,589,800
$2.69-0.23-7.9%$3.12$3.14$2.675,161,700
$2.92+0.09+3.2%$2.86$2.93$2.8052,293,900
$2.83+0.13+4.8%$2.76$2.89$2.6952,489,000
$2.70-0.02-0.7%$2.73$2.825$2.6817,028,800
$2.72+0.01+0.4%$2.80$2.945$2.713,512,900
$2.71+0.08+3.0%$2.65$2.73$2.632,493,500
$2.63-0.11-4.0%$2.70$2.71$2.591,680,500
$2.74+0.04+1.5%$2.72$2.815$2.661,687,100
$2.70+0.05+1.9%$2.68$2.72$2.622,463,600
$2.65-0.12-4.3%$2.77$2.77$2.622,543,400
$2.77-0.26-8.6%$3.06$3.06$2.772,963,000
$3.03-0.20-6.2%$3.20$3.215$3.012,275,700
$3.23+0.15+4.9%$3.04$3.23$3.041,390,400
$3.080.000.0%$3.09$3.13$3.001,378,100
$3.08+0.01+0.3%$3.09$3.23$2.981,678,500
$3.07+0.01+0.3%$3.00$3.155$2.981,225,200
$3.06-0.10-3.2%$3.12$3.14$3.0252,075,700
$3.16-0.14-4.2%$3.25$3.41$3.153,270,100
$3.30+0.12+3.8%$3.17$3.37$3.152,665,000
$3.18-0.10-3.0%$3.40$3.515$3.162,944,000
$3.28+0.28+9.3%$3.05$3.33$3.054,212,991
$3.00-0.11-3.5%$3.14$3.18$2.972,062,340
$3.11+0.17+5.8%$2.98$3.245$2.952,109,000
$2.94-0.31-9.5%$3.17$3.229$2.924,262,300
Ticker
NASDAQ:EDIT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Editas Medicine, Inc. news

Editas Medicine, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 188 in all · newest Nov 9, 2026 · oldest 2019
Calls
16 calls with a replay · 16 with a transcript · latest Aug 7, 2024
Decks
26 decks · latest November 2026

Where Editas Medicine, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:EDIT · Home listing · This pageNASDAQUnited StatesUSD
gettex:8EMgettexGermanyEUR
BOATS:EDITBOATSUnited StatesUSD
Tradegate:8EMTradegateGermanyEUR
LS Exchange:A2AC4KLS ExchangeGermanyEUR
Stuttgart:8EMStuttgartGermanyEUR
Lang & Schwarz:A2AC4KLang & SchwarzGermanyEUR
LSE:0IFKLSEUnited KingdomUSD
Frankfurt:8EMFrankfurtGermanyEUR
BX Swiss:8EMBX SwissSwitzerlandCHF
Dusseldorf:8EMDusseldorfGermanyEUR
Hamburg:8EMHamburgGermanyEUR
Munich:8EMMunichGermanyEUR

Valuation

EV/sales 2.4× against a median of 4.6×: 2nd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$119.7M USD
P/E
Loss
EV/sales
2.4×
EV/EBITDA
Negative EBITDA
Price/book
3.0×
Gross margin
99.0%
Operating margin
−151.7%
Net margin
−144.9%
Debt to equity
0.7×
Beta vs S&P 500
2.22

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.5MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.4Mn/an/an/a2.0×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Q32 Bio Inc. · NASDAQ:QTTBUS$249.6M−US$35.66M7.7×−0.7×−1.9×0.9×59.8%0.0×0.59
Turn Therapeutics Inc. · NASDAQ:TTRXUS$247.5MUS$244.2Mn/an/an/a43.5×n/a1.1×1.54
Mabpharm Limited · HKEX:2181US$247.3MUS$279.4M29.7×3.0×28.9×8.5×8.8%1.6×n/a
Median of the othersUS$256.3MUS$127.8M18.7×4.6×13.5×1.6×8.8%0.1×1.48

Forecasts

9 strong buy · 2 hold · 2 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
6.67 USD · Analysts' mean
EPS, year to Dec 2026
-0.81 · 5 analysts
Revenue, year to Dec 2026
29.94M · 3 analysts

Team and board

Officers

OfficerRole
Gilmore O’NeillPresident and Chief Executive Officer
Amy ParisonSenior Vice President and Chief Financial Officer
Damien GriersonSenior Vice President and General Counsel
Brieana BuckleySenior Vice President, Development and Program Leadership
Dan OryExecutive Vice President and Chief Medical Officer
Frank PanaccioSenior Vice President and Chief Business Officer
Gregory WhiteheadExecutive Vice President and Chief Technical and Quality Officer
Linda C. BurklyExecutive Vice President and Chief Scientific Officer
Tom LoveVice President, People

Board

DirectorRole
Jessica HopfieldChair
Andrew HirschBoard Member
Bernadette ConnaughtonBoard Member
David Scadden
Gilmore O’NeillPresident and Chief Executive Officer
Patrick T. EllinorBoard Member

Events

Next results
Mar 8, 2027 (expected)

Calls

CallWhenStatus
Editas Medicine (NASDAQ:EDIT) Q2 2024 Earnings CallWed, Aug 07, 2024 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q1 2024 Earnings CallWed, May 08, 2024 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q4 2023 Earnings CallWed, Feb 28, 2024 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q3 2023 Earnings CallTue, Nov 28, 2023 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q2 2023 Earnings CallWed, Aug 02, 2023 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q1 2023 Earnings CallFri, May 05, 2023 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q4 2022 Earnings CallWed, Feb 22, 2023 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q3 2022 Earnings CallWed, Nov 02, 2022 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q2 2022 Earnings CallWed, Aug 03, 2022 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q1 2022 Earnings CallWed, May 04, 2022 · 8:00 AM ETReplay
All 16 calls
CallWhenStatus
Editas Medicine (NASDAQ:EDIT) Q4 2021 Earnings CallThu, Feb 24, 2022 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q3 2021 Earnings CallMon, Nov 08, 2021 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q2 2021 Earnings CallWed, Aug 04, 2021 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q1 2021 Earnings CallWed, May 05, 2021 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q4 2020 Earnings CallThu, Feb 25, 2021 · 8:00 AM ETReplay
Editas Medicine (NASDAQ:EDIT) Q3 2020 Earnings CallThu, Nov 05, 2020 · 5:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+7.0%
Q2 2026Aug 5, 2026 · After close+5.5%
Q1 2026May 5, 2026 · Before open+1.3%
Q4 2025Feb 19, 2026+4.1%
Q3 2025Nov 10, 2025 · Before open+2.0%
Q2 2025Aug 12, 2025 · After close+34.5%
Q1 2025May 12, 2025 · After close−2.6%
Q4 2024Feb 26, 2025 · Before open−1.1%
Q3 2024Nov 4, 2024 · Before open−1.0%
Q2 2024Aug 7, 2024 · Before open−12.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open−11.4%
Q4 2023Feb 28, 2024 · Before open+24.9%
Q3 2023Nov 3, 2023 · Before open+18.2%
Q2 2023Aug 2, 2023 · Before open+5.7%
Q1 2023May 5, 2023 · Before open+12.0%
Q4 2022Feb 22, 2023 · Before open+6.2%
Q3 2022Nov 2, 2022 · Before open+1.1%
Q2 2022Aug 3, 2022 · Before open+13.4%
Q1 2022May 4, 2022 · Before open+11.5%
Q4 2021Feb 24, 2022 · Before open+10.1%

Open Events

Decks

DeckKindSlidesDate
American Heart Association Scientific Sessions 2026Conference15 slidesNovember 2026
Investor Presentation (June 2026)Investor deck17 slidesJune 2026
TIDES 2026Conference20 slidesMay 14, 2026
ASGCT 29th Annual Meeting 2026Conference20 slidesMay 2026
ASGCT 28th Annual Meeting 2025Conference8 slidesMay 2025
Investor Presentation (February 2025)Investor deck20 slidesFebruary 2025
2025 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRConference18 slidesFebruary 2025
EHA2024 Hybrid Congress (June 2024)Conference13 slidesJun 15, 2024
Technical Presentation (May 2024)Technical13 slidesMay 10, 2024
Technical Presentation (December 2023)Technical20 slidesDec 11, 2023
All 26 decks
DeckKindSlidesDate
Technical Presentation (June 2023)Technical26 slidesJun 12, 2023
EHA 2023 Hybrid CongressConference13 slidesJun 10, 2023
Technical Presentation (December 2022)Technical25 slidesDecember 2022
Technical Presentation (November 2022)Technical15 slidesNov 2, 2022
Technical Presentation (May 2022)Technical15 slidesMay 19, 2022
Technical Presentation (May 2022)Technical15 slidesMay 16, 2022
TIDES 2022Conference24 slidesMay 2022
TIDES 2021Conference33 slidesSep 23, 2021
TIDES USA 2021Conference25 slidesSep 23, 2021
Shareholder Meeting (May 2021)Shareholder meeting17 slidesMay 21, 2021
European Hematology Association 2020Conference13 slidesJune 2020
Keystone Symposia, Engineering the Genome/Emerging Cellular Therapies 2020Conference25 slidesFeb 10, 2020
Technical Presentation (October 2019)Technical21 slidesOctober 2019
Investor Presentation (May 2019)Investor deck30 slidesMay 9, 2019
Technical Presentation (2017)Technical22 slides2017
Technical Presentation (2017)Technical13 slides2017

Open Decks

Financings

RaiseDate
At-the-market programme of common stock
Tranche closed: US$17.3M raised
Use of proceeds: Fund operating expenses and capital expenditure requirements, extending cash runway into the third quarter of 2027
Nov 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Feb 2, 2016.

Price
US$16.00 a share
Shares offered
5,900,000 shares of common stock
Offering size
US$94.4 million
Underwriters' option
Up to 885,000 more shares
Listing
EDIT on the Nasdaq Global Select Market
Underwriters
Morgan Stanley, J.P. Morgan, Cowen and Company, JMP Securities · In the order on the cover
Shares delivered
On or about Feb 8, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceOct 16, 2015
Filed publiclyJan 4, 2016
Amended onceJan 25, 2016
Shares registered with an exchangeJan 29, 2016
Declared effective by the SECFeb 2, 2016
Final prospectus, with the priceFeb 3, 2016

Open IPO · From the cover of the final prospectus (424B1) filed Feb 3, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue40.5M32.3M78.1M19.7M25.5M90.7M20.5M31.9M13.7M6.05M
Cost of revenue5.28M199.2M6.06M6.34M5.05M158.0M96.9M90.7M83.2M57.0M
Gross profit40.5M-166.9M72.1M19.7M25.5M90.7M-76.4M-58.7M-69.4M-50.9M
Research and development90.0M199.2M177.7M175.0M142.5M158.0M96.9M90.7M83.2M57.0M
Selling, general and administrative49.9M72.0M69.7M70.7M76.2M67.6M64.6M55.0M50.5M46.3M
Operating income-160.0M-251.2M-169.2M-225.9M-193.1M-134.8M-140.9M-113.7M-119.9M-97.2M
Depreciation and amortization5.28M5.81M6.06M6.34M5.05M3.96M2.83M3.25M2.68M1.20M
EBITDA-154.7M-245.3M-163.1M-219.6M-188.1M-130.9M-138.1M-110.5M-117.3M-96.0M
Interest expense2.13M04.22M5.70M2.60M7.31M3.44M978.0K62.0K
Income before tax-160.1M-237.1M-153.2M-220.4M-192.5M-116.0M-133.7M-110.0M-120.3M-97.2M
Income tax00000-6.56M-10.3M-3.12M-1.12M-1.32M
Net income-160.1M-237.1M-153.2M-220.4M-192.5M-116.0M-133.7M-110.0M-120.3M-97.2M
Earnings per share, basic-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33-2.98-3.02
Earnings per share, diluted-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33-2.98-3.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents146.6M131.5M123.7M141.5M203.5M139.7M238.2M134.8M146.6M185.3M
Short-term investments0138.4M199.5M202.8M296.3M262.4M219.0M234.2M182.5M0
Receivables15.2M16.3M10.2M5.14M267.0K6.05M418.0K30.0K679.0K88.0K
Inventory-93.1M-120.1M-109.7M2.92M1.86M1.66M
Current assets163.9M289.3M340.8M356.8M507.3M419.1M463.8M374.8M332.2M187.2M
Property, plant and equipment3.54M14.5M12.0M15.6M17.1M14.0M10.9M40.2M39.4M40.4M
Goodwill00
Total assets186.5M341.6M499.2M514.3M677.5M572.6M508.9M420.4M373.3M229.2M
Accounts payable2.60M5.49M8.27M9.51M5.05M6.41M5.84M5.33M4.02M4.64M
Current liabilities46.2M77.2M63.2M60.1M46.9M58.2M60.0M35.9M36.7M33.1M
Long-term debt53.6M52.4M033.4M35.1M
Total debt58.6M57.4M043.9M26.4M26.1M29.1M45.2M40.9M45.1M
Total liabilities159.2M207.3M150.1M153.6M123.8M179.0M246.4M184.2M165.2M94.6M
Shareholders' equity27.3M134.3M349.1M360.7M553.6M393.6M262.4M236.2M208.1M134.6M
Shares outstanding97.9M82.7M81.8M68.8M68.4M62.6M54.4M48.8M44.5M35.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-165.2M-210.3M-132.2M-177.3M-163.8M-179.8M-40.7M-45.7M-9.42M-50.2M
Capital spending-607.0K-8.83M-4.72M-4.12M-7.98M-7.16M-6.17M-4.75M-2.06M-3.49M
Free cash flow-165.8M-219.1M-136.9M-181.5M-171.8M-187.0M-46.8M-50.5M-11.5M-53.7M
Cash from investing138.7M162.1M-3.73M114.1M-54.5M-140.5M12.3M-53.1M-183.8M-3.47M
Cash from financing40.5M56.0M118.0M1.28M282.1M224.1M131.8M86.9M154.5M97.2M
Dividends paid-4.00K-11.0K-782.0K
Share buybacks1.28M282.1M224.1M131.8M4.00K11.0K11.0K
Change in cash13.9M7.89M-17.9M-62.0M63.8M-96.2M103.4M-11.9M-38.7M43.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 8, 2026Current reportSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 9, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansSep 9, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 9, 2026Other filingsSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
S-3 · Registration statementAug 31, 2026Offer documentSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 21, 2026Other filingsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 3, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 3, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 2, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 29, 2026Other filingsSEC
424B5 · ProspectusMay 26, 2026Offer documentSEC
8-K · Current reportMay 26, 2026Material contractSEC
S-3MEFMay 26, 2026Other filingsSEC
8-K · Current reportMay 26, 2026Current reportSEC
424B5 · ProspectusMay 26, 2026Offer documentSEC
8-K · Current reportMay 26, 2026Current reportSEC
8-K · Current reportMay 14, 2026Current reportSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportApr 7, 2026Current reportSEC
8-K · Current reportMar 27, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
8-K · Current reportOct 9, 2025Current reportSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
8-K · Current reportSep 2, 2025Current reportSEC
144 · Notice of proposed saleAug 29, 2025Other filingsSEC
144 · Notice of proposed saleAug 29, 2025Other filingsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
144 · Notice of proposed saleJul 30, 2025Other filingsSEC
8-K · Current reportJun 12, 2025Current reportSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
144 · Notice of proposed saleJun 2, 2025Other filingsSEC
8-K · Current reportJun 2, 2025Management or board changeSEC
8-K · Current reportMay 14, 2025Current reportSEC
8-K · Current reportMay 13, 2025Current reportSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 15, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 15, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 15, 2025Meeting noticeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 8, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 24, 2025Other filingsSEC
8-K · Current reportMar 20, 2025Management or board changeSEC
POS AM · Amendment to an effective registrationMar 5, 2025Offer documentSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 5, 2025Offer documentSEC
10-K · Annual reportMar 5, 2025Annual reportSEC
8-K · Current reportMar 5, 2025ResultsSEC
POSASRMar 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 28, 2025Other filingsSEC
144 · Notice of proposed saleFeb 28, 2025Other filingsSEC
144 · Notice of proposed saleFeb 28, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025ResultsSEC
8-K · Current reportDec 17, 2024Management or board changeSEC
8-K · Current reportDec 12, 2024Management or board changeSEC
8-K · Current reportDec 9, 2024Current reportSEC
4 · Change in ownershipDec 5, 2024Insider tradeSEC
4 · Change in ownershipDec 5, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2024Quarterly reportSEC
8-K · Current reportNov 4, 2024ResultsSEC
8-K · Current reportOct 22, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
8-K · Current reportOct 3, 2024Material contractSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
144 · Notice of proposed saleAug 29, 2024Other filingsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
4 · Change in ownershipJul 26, 2024Insider tradeSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
144 · Notice of proposed saleJul 18, 2024Other filingsSEC
144 · Notice of proposed saleJul 18, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
8-K · Current reportJun 27, 2024Management or board changeSEC
8-K · Current reportJun 14, 2024Current reportSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
144 · Notice of proposed saleMay 31, 2024Other filingsSEC
144 · Notice of proposed saleMay 31, 2024Other filingsSEC
8-K · Current reportMay 31, 2024Meeting outcomeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
144 · Notice of proposed saleMay 17, 2024Other filingsSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 16, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
144 · Notice of proposed saleMar 4, 2024Other filingsSEC
S-3ASR · Registration statementFeb 28, 2024Offer documentSEC
S-8 · Registration statement for employee plansFeb 28, 2024Offer documentSEC
10-K · Annual reportFeb 28, 2024Annual reportSEC
8-K · Current reportFeb 28, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 24, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 10, 2024Big-stake noticeSEC
8-K · Current reportDec 13, 2023Current reportSEC
8-K · Current reportDec 11, 2023Current reportSEC
4 · Change in ownershipDec 7, 2023Insider tradeSEC
8-K · Current reportNov 22, 2023Management or board changeSEC
4 · Change in ownershipNov 16, 2023Insider tradeSEC
4 · Change in ownershipNov 9, 2023Insider tradeSEC
10-Q · Quarterly reportNov 3, 2023Quarterly reportSEC
8-K · Current reportNov 3, 2023ResultsSEC
8-K · Current reportOct 10, 2023Management or board changeSEC
4 · Change in ownershipSep 7, 2023Insider tradeSEC
4 · Change in ownershipAug 15, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
SC 13G · Big-stake noticeAug 4, 2023Big-stake noticeSEC
10-Q · Quarterly reportAug 2, 2023Quarterly reportSEC
8-K · Current reportAug 2, 2023ResultsSEC
4 · Change in ownershipJul 25, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 25, 2023Insider tradeSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
8-K · Current reportJun 15, 2023Material contractSEC

This page holds 200 of 733 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Editas Medicine, Inc.’s releases · as of Nov 6, 2026

Common shares
154,339,748
Fully diluted
154,339,748

Fully diluted

LineSharesAs of
Common shares154,339,748Nov 6, 2026

Share count over time

CountShares
Nov 6, 2026154,339,748

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock14.4M9.3%US$37MSep 30, 2026
Vanguard11.8M7.7%US$30.4MSep 30, 2026
TCG Crossover Management, LLC11.1M7.2%US$28.6MSep 30, 2026
Ra Capital Management, L.P.8.89M5.8%US$22.8MSep 30, 2026
Commodore Capital LP8.89M5.8%US$22.8MSep 30, 2026
ADAR1 Capital Management, LLC8.89M5.8%US$22.8MSep 30, 2026
Paradigm Biocapital Advisors LP7.58M4.9%US$19.5MSep 30, 2026
State Street7.04M4.6%US$18.1MSep 30, 2026
Geode Capital3.89M2.5%US$9.99MSep 30, 2026
Woodline Partners LP3.56M2.3%US$9.14MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vivo Capital, LLC3.56M2.3%US$9.14MSep 30, 2026
Opaleye Management Inc.3.49M2.3%US$8.96MSep 30, 2026
Goldman Sachs3.25M2.1%US$8.34MSep 30, 2026
D. E. Shaw & Co., Inc.3.19M2.1%US$8.2MSep 30, 2026
GordonMD Global Investments LP3.13M2.0%US$8.04MSep 30, 2026
Marshall Wace, LLP3.02M2.0%US$7.77MSep 30, 2026
Renaissance Technologies2.5M1.6%US$6.42MSep 30, 2026
Logos Global Management LP2.22M1.4%US$5.71MSep 30, 2026
Seven Fleet Capital Management LP1.92M1.2%US$2.94MSep 30, 2026
JPMorgan1.87M1.2%US$4.83MSep 30, 2026
UBS1.43M0.93%US$3.67MSep 30, 2026
Two Sigma1.32M0.86%US$3.39MSep 30, 2026
Raymond James Financial Inc1.32M0.85%US$3.39MSep 30, 2026
Kennedy Capital Management LLC1.3M0.84%US$3.35MSep 30, 2026
Schwab1.24M0.80%US$3.19MSep 30, 2026
Northern Trust1.19M0.77%US$3.07MSep 30, 2026
Ameriprise1.13M0.73%US$2.9MSep 30, 2026
HighVista Strategies LLC1.11M0.72%US$2.85MSep 30, 2026
AQR Capital Management LLC982K0.64%US$2.52MSep 30, 2026
Nantahala Capital Management, LLC853K0.55%US$2.19MSep 30, 2026
Acadian Asset Management LLC640K0.41%US$1.64MSep 30, 2026
Susquehanna631K0.41%US$1.62MSep 30, 2026
Los Angeles Capital Management LLC603K0.39%US$1.55MSep 30, 2026
Nuveen551K0.36%US$1.42MSep 30, 2026
Bank of America521K0.34%US$1.34MSep 30, 2026
Point72 Asset Management, L.P.513K0.33%US$1.32MSep 30, 2026
Barclays511K0.33%US$1.31MSep 30, 2026
Eversept Partners, LP457K0.30%US$1.17MSep 30, 2026
Casdin Capital, LLC445K0.29%US$1.14MSep 30, 2026
Morgan Stanley436K0.28%US$1.12MSep 30, 2026
BNY391K0.25%US$1MSep 30, 2026
Wellington365K0.24%US$938KSep 30, 2026
Invesco279K0.18%US$718KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.260K0.17%US$669KSep 30, 2026
LPL Financial LLC241K0.16%US$619KSep 30, 2026
Quadrature Capital Ltd237K0.15%US$608KSep 30, 2026
Citadel234K0.15%US$602KSep 30, 2026
Gsa Capital Partners LLP232K0.15%US$596KSep 30, 2026
Erste Asset Management GmbH230K0.15%US$596KSep 30, 2026
Millennium211K0.14%US$544KSep 30, 2026

This page holds 50 of 214 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund4.89M3.2%US$15.8MJun 30, 2026
iShares Russell 2000 ETF2.64M1.7%US$8.54MJun 30, 2026
Vanguard Strategic Equity Fund2.03M1.3%US$6.58MJun 30, 2026
Vanguard Extended Market Index Fund1.1M0.71%US$3.56MJun 30, 2026
Fidelity Small Cap Index Fund1.09M0.71%US$2.81MJul 31, 2026
iShares Russell 2000 Growth ETF844K0.55%US$2.73MJun 30, 2026
iShares Biotechnology ETF687K0.45%US$2.23MJun 30, 2026
Fidelity Extended Market Index Fund509K0.33%US$1.76MMay 31, 2026
Vanguard Russell 2000 Index Fund505K0.33%US$1.75MMay 31, 2026
Schwab U.S. Small-Cap ETF476K0.31%US$1.65MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Strategic Small-Cap Equity Fund415K0.27%US$1.35MJun 30, 2026
iShares Micro-Cap ETF337K0.22%US$1.09MJun 30, 2026
Vanguard Health Care Index Fund291K0.19%US$1.01MMay 31, 2026
JPMorgan Small Cap Value Fund279K0.18%US$904KJun 30, 2026
JPMorgan U.S. Small Company Fund279K0.18%US$903KJun 30, 2026
BlackRock Advantage Small Cap Growth Fund270K0.17%US$874KJun 30, 2026
Schwab Small-Cap Index Fund244K0.16%US$629KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account239K0.15%US$773KJun 30, 2026
BlackRock Advantage Small Cap Core Fund231K0.15%US$799KMay 29, 2026
Master Small Cap Index Series185K0.12%US$600KJun 30, 2026
Fidelity Total Market Index Fund174K0.11%US$602KMay 31, 2026
Fidelity Series Total Market Index Fund146K0.09%US$507KMay 31, 2026
Nuveen Small Cap Blend Index Fund133K0.09%US$344KJul 31, 2026
Ultra-Small Company Market Fund126K0.08%US$408KJun 30, 2026
iShares Russell 2000 Value ETF121K0.08%US$393KJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF119K0.08%US$307KJul 31, 2026
EQ/Small Company Index Portfolio112K0.07%US$361KJun 30, 2026
EQ/2000 Managed Volatility Portfolio101K0.07%US$329KJun 30, 2026
Schwab U.S. Broad Market ETF96,3500.06%US$333KMay 31, 2026
Multi-Manager Small Cap Equity Strategies Fund95,3930.06%US$330KMay 31, 2026
Strategic Advisers U.S. Total Stock Fund89,9160.06%US$311KMay 31, 2026
Vanguard Balanced Index Fund83,9850.05%US$272KJun 30, 2026
Fidelity Small Cap Growth Index Fund83,9650.05%US$272KJun 30, 2026
Nuveen Equity Index Fund77,3140.05%US$199KJul 31, 2026
Vanguard Russell 2000 Value Index Fund75,5170.05%US$261KMay 31, 2026
JPMorgan Small Cap Value Portfolio68,5960.04%US$222KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund66,9010.04%US$217KJun 30, 2026
Fidelity Nasdaq Composite Index Fund66,1340.04%US$229KMay 31, 2026
Schwab Total Stock Market Index Fund64,1200.04%US$165KJul 31, 2026
EQ/AB Small Cap Growth Portfolio62,9200.04%US$204KJun 30, 2026
LVIP JPMorgan Small Cap Core Fund62,2220.04%US$202KJun 30, 2026
LVIP State Street Small-Cap Index Fund61,9380.04%US$201KJun 30, 2026
AXS Green Alpha ETF61,1970.04%US$198KJun 30, 2026
Small Cap Value Fund56,8030.04%US$197KMay 31, 2026
Goldman Sachs Absolute Return Tracker Fund55,0420.04%US$178KJun 30, 2026
Global X Genomics & Biotechnology ETF54,7250.04%US$189KMay 31, 2026
Diversified Equity Alpha Master Portfolio53,3980.03%US$173KJun 30, 2026
Fidelity ZERO Total Market Index Fund53,0330.03%US$137KJul 31, 2026
Global X Russell 2000 ETF47,8230.03%US$123KJul 31, 2026
Small Cap Index Fund46,2070.03%US$150KJun 30, 2026

This page holds 50 of 142 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Burkly Linda
Officer: EVP, CHIEF SCIENTIFIC OFFICER
Sale7,814USD 2.42US$18,875Nov 11, 2026
O'Neill Gilmore Neil
Director, Officer: CEO
Sale21,164USD 2.42US$51,122Nov 11, 2026
O'Neill Gilmore Neil
Director, Officer: CEO
Sale5,124USD 3.04US$15,577Sep 3, 2026
Burkly Linda
Officer: EVP, CHIEF SCIENTIFIC OFFICER
Sale709USD 3.04US$2,155Sep 3, 2026
Parison Amy
Officer: SVP, Chief Financial Officer
Sale453USD 3.04US$1,377Sep 3, 2026
Parison Amy
Officer: SVP, Chief Financial Officer
Sale678USD 2.58US$1,749Aug 3, 2026
Burkly Linda
Officer: EVP, CHIEF SCIENTIFIC OFFICER
Sale4,928USD 2.67US$13,158Jul 28, 2026
Burkly Linda
Officer: EVP, CHIEF SCIENTIFIC OFFICER
Sale731USD 2.70US$1,974Jun 3, 2026
O'Neill Gilmore Neil
Director, Officer: CEO
Sale15,380USD 2.70US$41,526Jun 3, 2026
Parison Amy
Officer: SVP, Chief Financial Officer
Sale464USD 2.70US$1,253Jun 3, 2026

Big stakes

StakeStakeSharesDateFiling
TCG Crossover GP III, LLC9.90%15.8MMay 27, 2026Schedule 13G
Commodore Capital LP9.90%16MMay 26, 2026Schedule 13G
BlackRock, Inc.7.80%11.9MSep 30, 2026Schedule 13G
ADAR1 Capital Management, LLC5.80%8.89MJun 30, 2026Schedule 13G
Ra Capital Management, L.P.5.80%8.89MMay 27, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Douglas G Cole
Other companies: Foghorn Therapeutics Inc. (Director · Since at least Oct 22, 2020); Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Aug 10, 2016 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past)
Director · Feb 2, 2016 – Aug 17, 2017 · Past
Andrew A F Hack
Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Nuvalent, Inc. (Director · Jul 28, 2021 – Dec 11, 2024 · Past); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); BCLS Acquisition Corp (Chief Financial Officer, Director · Oct 21, 2020 – Oct 26, 2020 · Past); Dynavax Technologies Corporation (Director · Aug 12, 2019 – Aug 8, 2023 · Past); Allena Pharmaceuticals Inc (Director · Jun 8, 2018 – Nov 17, 2020 · Past)
Chief Financial Officer · Feb 2, 2016 – Feb 4, 2019 · Past
John Mendlein
Other companies: Fate Therapeutics, Inc. (Director · Since at least Sep 30, 2013); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past); Moderna, Inc. (See Remarks · Dec 7, 2018 – Dec 7, 2018 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 8, 2019 · Past)
Director · Feb 2, 2016 – Jun 15, 2017 · Past
Akshay Vaishnaw
Other companies: Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); Scholar Rock Holding Corporation (President of R&D · Since at least May 21, 2019); Alnylam Pharmaceuticals, Inc. (President · Mar 4, 2009 – Aug 3, 2023 · Past)
Director · Jul 28, 2016 – May 30, 2024 · Past
Andrew Hirsch
Other companies: C4 Therapeutics, Inc. (President and Chief Executive Officer, Director · Since at least Oct 1, 2020); Agios Pharmaceuticals, Inc. (Chief Financial Officer · Sep 19, 2016 – Apr 22, 2020 · Past); BIND Therapeutics Inc (PRESIDENT & CEO, Director · Sep 19, 2013 – Jun 22, 2015 · Past)
Board Member · Since at least May 30, 2017
David Scadden
Other companies: Agios Pharmaceuticals, Inc. (Independent Director · Since at least May 27, 2017); Carisma Therapeutics, Inc. (Director · Jun 30, 2024 – Jul 1, 2024 · Past); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past)
Director · Since at least Feb 5, 2019
Gilmore O’Neill
Other companies: Aptinyx Inc (Director · Oct 19, 2021 – May 26, 2022 · Past); Unity Biotechnology Inc (Director · Dec 10, 2020 – Jun 21, 2024 · Past); Sarepta Therapeutics, Inc. (EVP, R&D & CMO · Jun 7, 2018 – Mar 3, 2021 · Past)
President and Chief Executive Officer · Since at least Jun 1, 2022
Michelle Robertson
Other companies: Geron Corporation (Executive Vice President, Chief Financial Officer and Treasurer · Since at least Sep 25, 2023); Verastem, Inc. (Member, Audit Committee; Member, Compensation Committee · Since at least Nov 15, 2021); Momenta Pharmaceuticals Inc (Chief Financial Officer · Oct 5, 2018 – Oct 25, 2019 · Past)
EVP, CHIEF FINANCIAL OFFICER · Jan 9, 2020 – May 11, 2023 · Past
Bernadette Connaughton
Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Sep 7, 2018); Syneos Health Inc (Director · Nov 12, 2019 – Sep 28, 2023 · Past)
Board Member · Since at least Oct 26, 2021
Elliott Levy
Other companies: NuCana plc (Non Executive Director · Since at least Mar 18, 2026); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past)
Director · Since at least Apr 11, 2023
All 29 people
PersonSeat
Jessica Hopfield
Other companies: Maravai LifeSciences Holdings, Inc. (Director · Since at least May 23, 2024); Insulet Corporation (Director · Since at least May 22, 2024)
Chair · Since at least May 13, 2024
Kevin Bitterman
Other companies: Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Akero Therapeutics Inc (Director · Jun 19, 2019 – Jun 1, 2021 · Past)
Director · Feb 2, 2016 – Jun 15, 2017 · Past
James C Mullen
Other companies: Thermo Fisher Scientific Inc (Director · May 18, 2022 – May 21, 2025 · Past)
CEO, Director · Apr 14, 2022 – Apr 14, 2022 · Past
Amy ParisonSenior Vice President and Chief Financial Officer · Since at least May 12, 2025
Brieana BuckleySenior Vice President, Development and Program Leadership · Since at least Nov 4, 2026
Charles AlbrightEVP/Chief Scientific Officer · Aug 22, 2016 – Dec 15, 2020 · Past
Damien GriersonSenior Vice President and General Counsel · Since at least Nov 5, 2026
Daniel Scott OryEVP, Chief Medical Officer · Since at least Sep 8, 2026
Dan OryExecutive Vice President and Chief Medical Officer · Since at least Oct 8, 2026
Frank PanaccioSenior Vice President and Chief Business Officer · Since at least Nov 4, 2026
Gregory WhiteheadExecutive Vice President and Chief Technical and Quality Officer · Since at least Nov 5, 2026
Katrine BosleyPresident and CEO, Director · Feb 2, 2016 – Jan 8, 2019 · Past
Linda C. BurklyExecutive Vice President and Chief Scientific Officer · Since at least Jul 24, 2023
Lisa Anne MichaelsEVP/Chief Medical Officer · Nov 9, 2020 – Dec 22, 2021 · Past
Mark S ShearmanEVP, CHIEF SCIENTIFIC OFFICER · Jun 14, 2021 – Feb 13, 2023 · Past
Patrick T. EllinorBoard Member · Since at least Aug 5, 2026
Patrick Thomas Ellinor IIDirector · Since at least Aug 6, 2026
Tom LoveVice President, People · Since at least Nov 4, 2026
Vickesh MyerChief Technology Officer · Jun 15, 2018 – Mar 18, 2019 · Past

Open People

Log in to ask 6ix AI your own questions about Editas Medicine, Inc.